|
Vol. 6, No. 1 Release date: May 5, 2008 Table of Contents |
||||
| Instructions for Participation | ||||
|
||||
| Overview and Purpose | ||||
Inflammatory breast cancer (IBC) is a particularly aggressive form of the disease that overexpresses the ErbB2 receptor approximately twice as often as noninflammatory breast tumors. Antibody-based therapies and small-molecule tyrosine kinase inhibitors that target dysregulated ErbB signaling have demonstrated significant clinical benefit for patients with ErbB2+ breast cancer. Ongoing studies are investigating ErbB2-targeted agents in tumors with specific pathologic characteristics such as IBC and in patients who have progressed on ErbB2-targeted therapy. The continued development and optimization of drugs that target ErbB2-mediated signaling will involve evaluation of their efficacy and safety in particular patient populations, such as those with IBC or central nervous system metastases. The purpose of this activity is to update physicians on the latest data on the use of ErbB2-targeted agents in the treatment of patients with ErbB2+ metastatic IBC. |
||||
| Target Audience | ||||
| This activity is intended for medical oncologists involved in the care of patients with breast cancer. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity. | ||||
| Learning Objectives | ||||
| Upon completion of this educational activity, you should be able to: | ||||
|
||||
| Accreditation and Credit Designation | ||||
| Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
||||
| Disclosure Policy | ||||
| It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.
Patricia M. LoRusso, DO Mary Jo Pilat, PhD, MS, PA-C
PER Editorial Staff This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the first page of the article. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings. | ||||
| Commercial Support | ||||
Case Studies in Breast Cancer is produced by Physicians’ Education Resource, Dallas, TX. An educational grant for this activity was provided by GlaxoSmithKline. |
||||
| Software Requirements | ||||
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser. If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About. PC UsersIf you need to upgrade your Web browser, follow one of the links listed below:
Compatible Web browsers include Firefox (Outside Source) and Apple Safari (Outside Source). |
||||
| Illustration | ||||
| Photographs of skin lesions of a patient with inflammatory breast cancer on day 1 of treatment with lapatinib (top panel) and revealing a partial response at month 5 (bottom panel). | ||||
| Disclaimer | ||||
| The views and opinions expressed in this activity are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. Please consult full prescribing information for any drugs or procedures discussed within. |
||||
| Privacy Policy | ||||
Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045. All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher. ©Copyright 2008 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher. All correspondence should be directed to: |
||||
|
|
||||
